Zacks Investment Research cut shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a report released on Tuesday.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Several other brokerages have also weighed in on CAPR. Maxim Group reissued a buy rating and issued a $4.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, November 14th. HC Wainwright reissued a buy rating and issued a $9.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, November 20th. ValuEngine lowered Capricor Therapeutics from a hold rating to a sell rating in a report on Friday, December 7th. Finally, TheStreet lowered Capricor Therapeutics from a c- rating to a d+ rating in a report on Monday, October 15th. Two research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $4.83.
Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.90 million. Capricor Therapeutics had a net margin of 24.75% and a negative return on equity of 159.36%. As a group, research analysts anticipate that Capricor Therapeutics will post -0.57 EPS for the current fiscal year.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Article: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.